92
THE MECHANISMS OF PROTEINURIA AND ITS SIGNIFICANCE AS AN
OUTCOME INDICATOR IN CHRONIC KIDNEY DISEASE
Islomova Mohinur Tolib kizi
Alfraganus University, Tashkent, Uzbekistan.
Tashkent city, Yunusabad district, Yukori Karakamish st 2a-house:
Email: info@alfraganusuniversity.uz +998781227557
https://doi.org/10.5281/zenodo.14523425
Abstract:
Chronic kidney diseases (CKD) share common pathological mechanisms that,
regardless of the initial cause, lead to glomerular hyperfiltration, proteinuria, progressive
renal scarring, and loss of kidney function. Substantial experimental evidence highlights the
pivotal role of proteinuria in accelerating CKD progression to end-stage renal failure through
various pathways, including the induction of tubular chemokine expression and complement
activation. These processes trigger interstitial inflammatory cell infiltration and persistent
fibrogenesis. Proteinuria is widely acknowledged as a key marker of CKD severity and a
predictor of future declines in glomerular filtration rate. Furthermore, reducing proteinuria
consistently correlates with slower renal function decline in both diabetic and non-diabetic
kidney disease. Emerging data also reveal a link between proteinuria levels and
cardiovascular risk, extending even to levels of urinary albumin excretion previously
considered within the 'normal' range. Thus, proteinuria serves as a valuable surrogate
endpoint in clinical trials for CKD and an important therapeutic target for reno- and
cardioprotective strategies.
Keywords
: biomarker, cardiovascular, chronic kidney disease, proteinuria.
Introduction
Chronic kidney disease (CKD) affects approximately 5–7% of the global population and
poses a significant health burden, with affected individuals facing higher risks of
hospitalization and cardiovascular disease compared to their peers of similar age and gender
in the general population. A cohort study involving nearly 1.3 million participants revealed
that unadjusted mortality rates following myocardial infarction were markedly higher in
individuals with CKD compared to those with pre-existing cardiovascular disease or diabetes
[1]. Due to its largely asymptomatic nature, CKD often goes undiagnosed, with four out of five
affected individuals unaware of their condition as they progressively lose renal function over
time. Tragically, half of CKD patients succumb to cardiovascular events before reaching end-
stage renal disease (ESRD), and nearly two-thirds of patients initiating dialysis die within five
years—a life expectancy worse than that seen in patients with heart failure or many common
cancers.
The substantial burden of CKD, coupled with its associated costs, adverse health
outcomes, and reduced productivity, underscores its status as a global public health challenge
[2]. This problem is even more acute in low-resource settings, where ESRD often represents a
"death sentence" due to limited access to dialysis or kidney transplantation, leading to the
deaths of nearly one million ESRD patients annually.
While advances in CKD prevention and management have improved patient outcomes in
recent decades, the number of individuals progressing to ESRD remains alarmingly high [3].
Experimental studies have spurred the development of new therapeutic options, yet
93
disappointingly few nephroprotective treatments have reached clinical application. The slow,
progressive nature of CKD adds to the difficulty of designing clinical trials with definitive
endpoints such as the need for renal replacement therapy or mortality. Although the doubling
of serum creatinine is recognized by the Food and Drug Administration (FDA) as a surrogate
endpoint, its utility in clinical trials is limited, as several years are often required for this
outcome to manifest.
Proteinuria as a Key Risk Factor in Renal Disease Progression
Proteinuria is a well-established risk factor for the progression of chronic kidney disease
(CKD) in both diabetic and non-diabetic populations. A large-scale screening of 107,192
individuals in Okinawa, Japan, identified proteinuria as the strongest predictor of end-stage
renal disease (ESRD) over a 10-year period in the general population. Similarly, in the
Ramipril Efficacy in Nephropathy (REIN) trial, which included 274 patients with non-diabetic
chronic nephropathies and clinical proteinuria, urinary protein excretion was the only
baseline variable significantly correlated with the rate of glomerular filtration rate (GFR)
decline and progression to ESRD. When stratified by baseline proteinuria levels, patients in
the lowest tertile had slower rates of CKD progression and lower risk of ESRD compared to
those in the middle and highest tertiles. Consistent findings were observed in the Modification
of Diet in Renal Disease (MDRD) study and the African-American Study of Kidney Disease and
Hypertension (AASK), where higher baseline proteinuria predicted a more rapid decline in
GFR in non-diabetic CKD patients.
The same pattern is observed in diabetic patients. The UK Prospective Diabetes Study 74
demonstrated that even increases in urinary albumin within the normal range were
independently associated with the future development of microalbuminuria (urine albumin
excretion of 30–300 mg/24 h) or renal impairment in type 2 diabetic patients without
baseline albuminuria. Furthermore, in patients with diabetic nephropathy, the baseline
urinary albumin-to-creatinine ratio was identified as a strong independent predictor of ESRD
in both the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) study and the Irbesartan in Diabetic Nephropathy Trial (IDNT).
Proteinuria's Pathogenic Role in Renal Function Decline
Experimental studies have provided crucial insights into the mechanisms underlying the
progression of chronic kidney disease (CKD). It is now well recognized that chronic
proteinuric nephropathies, regardless of their primary cause, share a common feature: a loss
of selectivity in the glomerular barrier, allowing excessive protein filtration. In an
experimental model of renal mass reduction via five-sixths nephrectomy, the remaining
glomeruli undergo hypertrophy, accompanied by a disproportionate reduction in the tone of
afferent arterioles compared to efferent ones. These adaptations result in increased
glomerular capillary hydraulic pressure and elevated single-nephron filtration rates. While
initially compensatory, these changes eventually inflict progressive damage on the remaining
intact nephrons. Elevated intraglomerular capillary pressure stretches the glomerular
capillaries, impairing their filtering capacity and leading to the loss of larger molecules, such
as proteins, into the urine. Recent findings have identified a direct link between podocyte
detachment, endothelial cell fenestration, and albuminuria in patients with type 2 diabetes.
Similar correlations observed in type 1 diabetes demonstrate that these structural
94
abnormalities worsen alongside the classic histological features of diabetic kidney disease,
establishing a connection between glomerular injury, albuminuria, and renal scarring.
These findings support the hypothesis that tubulointerstitial damage is mediated by the
direct toxicity of filtered proteins. Excessive protein loading of podocytes has been implicated
in their progressive injury, with subsequent release of transforming growth factor-β (TGF-β),
which induces mesangial cell differentiation into myofibroblasts. In vitro studies have shown
that proximal tubular cells exposed to plasma proteins such as albumin, IgG, and transferrin
release profibrotic and pro-inflammatory molecules, including endothelin-1 (ET-1), RANTES,
and osteopontin. Protein overloading of human proximal tubular cells also stimulates the
synthesis of fractalkine, a membrane-anchored chemokine that promotes mononuclear cell
adhesion via the CX3CR1 receptor. Increased fractalkine gene expression has been observed
in the kidneys of mice with protein overload proteinuria, with the protein product localized
predominantly in the basal regions of tubular epithelial cells.
Reducing Proteinuria Slows Renal Disease Progression
Clinical trials have consistently demonstrated the renoprotective effects of reducing
proteinuria. The MDRD study established that proteinuria reduction achieved through
antihypertensive therapy was associated with a slower rate of glomerular filtration rate (GFR)
decline. Importantly, the degree of renal protection conferred by blood pressure reduction
was closely linked to the baseline level of proteinuria.
The REIN study further supported this concept by investigating the hypothesis that
angiotensin-converting enzyme (ACE) inhibitors could provide superior renoprotection
compared to other antihypertensive agents due to their antiproteinuric effects. In this study,
patients with chronic nephropathies were randomized to receive ramipril or conventional
antihypertensive therapy to maintain diastolic blood pressure at or below 90 mmHg. Despite
achieving similar blood pressure control in both groups, ACE inhibitor therapy resulted in
significantly greater reductions in proteinuria and a 50% lower risk of progression to ESRD.
Patients with higher baseline proteinuria levels derived greater benefit from treatment, but
regardless of the initial proteinuria level, short-term reductions in proteinuria were strongly
correlated with slower rates of GFR decline and lower long-term risk of ESRD.
Similar findings have been observed in diabetic kidney disease. In type 1 diabetics with
overt nephropathy, enalapril was shown to slow GFR decline more effectively than β-
adrenoceptor blockers, despite comparable blood pressure control. Another trial involving
409 type 1 diabetics revealed that captopril reduced the risk of reaching the combined
endpoint of doubling serum creatinine, ESRD, or death compared to placebo, with slower
progression linked to greater reductions in proteinuria.
In type 2 diabetics, large clinical trials have shown that proteinuria reduction through
angiotensin receptor blockers is associated with reduced incidence of serum creatinine
doubling and lower risk of ESRD. Post hoc analyses from numerous randomized clinical trials
have consistently found that short-term reductions in proteinuria are invariably associated
with slower GFR decline and decreased progression to ESRD in the long term. These findings
underscore the critical role of proteinuria reduction as a therapeutic target in slowing CKD
progression.
Proteinuria as a Cardiovascular Risk Factor
95
In addition to its role in renal disease progression, proteinuria is a significant risk factor
for cardiovascular events and mortality in both diabetic and non-diabetic populations.
Patients with proteinuria face an elevated risk of cardiovascular events, cardiovascular-
related deaths, and all-cause mortality. Proteinuria has also been linked to myocardial
changes in the left ventricle, a higher incidence of stroke, and an increased risk of
atherosclerotic events in the peripheral vasculature.
The RENAAL study, which included 1,513 patients with type 2 diabetes randomized to
receive either losartan or placebo, demonstrated that each 50% reduction in albuminuria
corresponded to an 18% reduction in cardiovascular risk and a 27% reduction in heart failure
risk. Similar findings were reported in the LIFE trial, where reductions in albuminuria over
time were associated with a lower risk of the primary composite cardiovascular endpoint. In
both studies, greater reductions in proteinuria not only slowed renal disease progression but
also significantly reduced cardiovascular events. Consistent results were observed in the
IDNT trial, which included type 2 diabetes patients with overt nephropathy.
These findings highlight the dual reno- and cardioprotective benefits of interventions
that reduce urinary albumin or total protein excretion. Proteinuria and albuminuria are
therefore highly sensitive and reliable surrogate endpoints for monitoring and predicting the
effectiveness of treatments in both clinical and research settings.
Conclusion
Surrogate endpoints for renal failure are crucial for evaluating new treatments in
patients with chronic kidney disease (CKD), whose condition typically progresses slowly and
asymptomatically. Proteinuria directly contributes to renal disease progression and is widely
accepted as an indicator of the severity of glomerulopathy. Both population-based studies and
controlled trials have demonstrated that proteinuria predicts a decline in glomerular filtration
rate (GFR) and the onset of end-stage renal disease (ESRD). Reducing proteinuria consistently
leads to a slower decline in renal function in both diabetic and non-diabetic patients with
significant proteinuria. More importantly, lowering proteinuria and preserving kidney
function also results in better cardiovascular outcomes. Therefore, proteinuria should be
regarded as an important surrogate endpoint for clinical trials in proteinuric renal diseases
and a key target for cardiovascular protection.
Although proteinuria has not yet been officially recognized as a surrogate endpoint by
the FDA or the European Medicines Agency (EMA) for CKD treatment trials, the compelling
evidence has sparked a productive discussion among top nephrologists and FDA officials
regarding its qualification as a surrogate marker.
References:
1.
Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn
BR. Risk of coronary events in people with chronic kidney disease compared with those with
diabetes: a population-level cohort study.
Lancet
. 2012;380:807–814. doi: 10.1016/S0140-
6736(12)60572-8. [PubMed] [Google Scholar]
2.
Donadelli R, Zanchi C, Morigi M, Buelli S, Batani C, Tomasoni S, Corna D, Rottoli D,
Benigni A, Abbate M, Remuzzi G, Zoja C. Protein overload induces fractalkine upregulation in
proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein
96
kinase-dependent
pathways.
J
Am
Soc
Nephrol
.
2003;14:2436–2446.
doi:
10.1097/01.asn.0000089564.55411.7f. [PubMed] [Google Scholar]
3.
Cravedi P, Ruggenenti P, Remuzzi G. Kidney failure stabilizes after an increase over 2
decades.
J Ren Care
. 2007;33:100–104. doi: 10.1111/j.1755-6686.2007.tb00052.x. [PubMed]
[Google Scholar]
4.
Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Hall PM. Performance of
the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill
hospitalized patients.
Am J Kidney Dis
. 2005;46:242–252. doi: 10.1053/j.ajkd.2005.04.023.
[PubMed] [Google Scholar]
5.
Ruggenenti P, Gaspari F, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Prandini S,
Ene-Iordache B, Diadei O, Perico N, Ondei P, Pisani A, Buongiorno E, Messa P, Dugo M,
Remuzzi G. Measuring and estimating GFR and treatment effect in ADPKD patients: results
and implications of a longitudinal cohort study.
PLoS ONE
. 2012;7:e32533. doi:
10.1371/journal.pone.0032533. [PMC free article] [PubMed] [Google Scholar]
6.
Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD.
Nat Rev Nephrol
. 2012;8:301–306. doi: 10.1038/nrneph.2012.42. [PubMed] [Google Scholar]
7.
Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a
cohort of mass screening.
Kidney Int
. 1996;49:800–805. doi: 10.1038/ki.1996.111. [PubMed]
[Google Scholar]
8.
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G.
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The
‘Gruppo Italiano di Studi Epidemiologici in Nefrologia’ (GISEN).
Kidney Int Suppl
.
1997;63:S54–57. [PubMed] [Google Scholar]
9.
Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S,
Massry SG, Seifter JL; Group ftMoDiRDMS. Blood pressure control, proteinuria, and the
progression of renal disease. The modification of diet in renal disease study.
Ann Intern Med
.
1995;123:754–762. doi: 10.7326/0003-4819-123-10-199511150-00003. [PubMed] [Google
Scholar]
10.
Wright JT, Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-
Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD,
Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class
on progression of hypertensive kidney disease: results from the AASK trial.
JAMA
.
2002;288:2421–2431. doi: 10.1001/jama.288.19.2421. [PubMed] [Google Scholar]
